Piperacillin Sodium + Tazobactam SodiumThird Party Manufacturing in India

The combination of Piperacillin Sodium and Tazobactam Sodium works through a dual mechanism to treat severe bacterial infections. Piperacillin, a broad-spectrum ureidopenicillin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial lysis. Tazobactam Sodium, a penicillanic acid sulfone derivative, is a beta-lactamase inhibitor that binds irreversibly to beta-lactamase enzymes produced by resistant bacteria. This prevents the enzymatic degradation of piperacillin, preserving its bactericidal activity against a wide variety of beta-lactamase-producing pathogens.

Therapeutic Uses

Piperacillin Sodium + Tazobactam Sodium is prescribed for moderate-to-severe infections:

• Intra-Abdominal Infections: Treats appendicitis, peritonitis, and deep abdominal abscesses.
• Pneumonia: Indicated for community-acquired and nosocomial pneumonia in hospital settings.
• Skin and Skin Structure Infections: Treats cellulitis, ischemic ulcers, and diabetic foot infections.
• Gynecological Infections: Treats postpartum endometritis and pelvic inflammatory disease.
• Febrile Neutropenia: Used as empiric treatment in patients with concurrent neutropenia.

Why Manufacturers Choose Piperacillin + Tazobactam

Piperacillin + Tazobactam is a gold-standard intravenous antibiotic widely used in hospital intensive care units (ICUs) and emergency rooms. This makes it a high-volume product in public and private institutional tenders. Sourcing from a WHO-GMP certified facility with dedicated beta-lactam dry powder sterile filling blocks is critical to satisfy strict regulatory requirements.

By securing Piperacillin + Tazobactam third party manufacturing in India, distributors and PCD franchise operators can offer a premium, critical-care antibiotic in standard strengths (1.125g, 2.25g, and 4.5g). India's advanced sterile injectable capacity ensures high-purity filling, extended shelf-life, and consistent batch delivery.